CPHI Expands to Serve Russias Rapidly Growing Pharma Market
AMSTERDAM, 9 October 2012 — Leading event organiser, UBM Live, today announced the launch of CPHI Russia at IPhEB as the latest expansion of its global pharmaceutical events. UBM Live actively sought a partnership with RESTEC, respected Russian organiser of IPhEB, the St. Petersburg International Forum for Pharmacy, Medical Equipment, Biotechnology and Radiology to facilitate access to the Russian market. The events will bring together the senior Russian pharma professionals who attend IPhEB with the global pharmaceutical suppliers and buyers who attend CPHI. The events will be co-located and held on April 10 -11, 2013 in Manege Central Exhibition Hall in St. Petersburg.
The Russian pharmaceutical market experienced high double-digit growth in recent years and is positioned firmly at the forefront of pharmerging markets. Russia is currently the eleventh largest pharmaceutical market in the world and is projected to reach a value of US $26.7 billion by the end of 2013. The Russian Government's ambitious Pharma 2020 plan, introduced in 2009, includes funding of nearly US$5 billion and seeks to dramatically increase domestic pharmaceutical manufacturing and R&D capabilities. As a result of the Pharma 2020 plan the demand for pharmaceutical ingredients and manufacturing and packaging equipment will be increasing dramatically in order to upgrade existing manufacturing sites to GMP standards.
“The Russian pharmaceutical market is set for tremendous growth: this year we already have seen leading pharmaceutical companies, such as Novartis and AstraZeneca, opening manufacturing sites and R&D centres in the St. Petersburg region and other parts of Russia. We believe our industry leading face-to-face events and digital products can play a critical role in accelerating that growth and driving innovation in the Russian pharmaceutical market,” noted Andrew Pert, Brand Director for CPHI Russia.
UBM Live’s survey results from visitors to the Frankfurt CPHI Worldwide event in 2011 showed that 42 percent of attendees were already actively working in the Russian pharmaceutical market, and more than one third had plans to enter the market over the next two years.
“We feel that this is the right time to introduce a top-level networking event that can help to facilitate successful entry into this market for our customer base and are delighted to collocate with the well established IPhEB Forum,” added Pert. In 2012 the event was strongly supported by the national government, including support from The Ministry of Industry and Trade of the Russian Federation, The Chamber of Commerce and Industry of the Russian Federation, St. Petersburg City Administration and the Committee for Economic Development, Industrial Policy and Trade.
Bringing CPHI to Russia is a logical next step after the debut of a dedicated Russian Pavilion at CPHI Worldwide 2012 with support from the Ministry of Industry and Trade of the Russian Federation. CPHI Worldwide will also host high profile exhibitors from Russia, including Indukern-Rus, R&D Pharma, P & M Invest, INVAR and Dalchem.
To learn more about CPHI Russia at IPhEB, please visit www.cphi-russia.com.
The annual UBM Live Pharma Portfolio of events also includes CPHI Worldwide, ICSE, P-MEC Europe and InnoPack (9-11 October, 2012 at the Feria de Madrid in Spain); CPHI, ICSE, P-MEC India and BioPh (21-23 November, 2012 at the Bombay Exhibition Centre in Mumbai); CPHI, P-MEC, InnoPack South East Asia (20-22 March, 2013 at the Jakarta International Expo in Indonesia); CPHI, ICSE, P-MEC, BioPh and Pharmatec Japan (24-26 April, 2013 at the Tokyo Big Sight Exhibition Centre in Japan); CPHI, P-MEC, ICSE, InnoPack, LABWorld, BioPh China (25-27 June 2013 at the SNIEC in Shanghai); and CPHI South America (6-8 August 2013 at the Expo Centre Norte, Sao Paulo, Brazil).
About UBM Live:
UBM Live is a division of UBM Plc (LSE: UBM) a leading provider of business information services to the maritime, travel, fashion, technology, healthcare, media, and property industries. UBM offers services in trade shows, online, news distribution, and publishing to customers across the globe. Its brands are represented in more than 30 countries and are organized into specialist teams that serve their business communities helping them excel in their market by working effectively and efficiently. For more information, go to www.ubmlive.com.
About RESTEC® Exhibition Company:
RESTEC® Exhibition Company is one of the top three leaders of the Russia`s exhibition business. The optimal structure formed by RESTEC® let us combine exhibition, congress, business and contest programs that altogether foster effective work of our exhibitors, participants, delegates and trade visitors. At this point our exhibition and congress events continue developing as centers of international business networking with the constantly growing number of countries and participants represented. For more information, go to www.restec.ru/en.
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation.
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field.
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke...
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA).
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors stateDoctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients.
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre...
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts.
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
Generate high-quality, engaged leads for your business, all year round
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
Your company’s profile boosted at all participating CPHI events
An easy-to-use platform with a detailed dashboard showing your leads and performance